Abstract Background/Aims: Increasing evidence demonstrates that long non-coding RNAs (lncRNAs) regulate diverse cellular processes and cancer progression. Whether lncRNAs play any functional role in colorectal carcinoma (CRC) remains largely unknown. The aim of this study was to investigate the role of lncRNA CPS1 intronic transcript 1 (CPS1-IT1) in CRC. Methods: Expression of CPS1-IT1 was initially assessed in human CRC tissues and in a series of CRC cell lines. The correlations between CPS1-IT1 levels and survival outcomes were analyzed to elucidate the clinical significance of CPS1-IT1 in CRC. The underlying mechanisms of CPS1-IT1 in CRC were analyzed through in vitro and in vivo functional assays. Results: Expression of CPS1-IT1 was significantly decreased in CRC tissues and cell lines, and patients with low CPS1-IT1 expression had poor survival outcomes. The results of in vitro assays revealed that CPS1-IT1 significantly reduced cell proliferation, migration and invasion capacities and accelerated cell apoptosis, thereby suppressing epithelial-mesenchymal transition (EMT). An in vivo animal model also demonstrated the tumor-suppressive role of CPS1-IT1. Conclusion: In this study, we found that CPS1-IT1 has a tumor-suppressive role in CRC. Our data suggest that CPS1-IT1 could be used as a new prognostic biomarker and therapeutic target for CRC.
Introduction
Colorectal carcinoma (CRC) is a type of malignant neoplasm in the human digestive tract with a high morbidity rate. Its incidence and mortality are ranked third and fourth highest [1, 2] , respectively, of all malignant tumors. Therefore, it is regarded as a serious threat to human health. Because of economic development and changes in people's lifestyle, the incidence of CRC is much higher than before [3] . However, in recent years, the rising morbidity rate of CRC has slowed down [4] . However, because of its subclinical manifestations and its characteristic poor
Cell Culture
Colorectal cancer cell lines (LoVo, SW620, SW480, LS174T, HCT116 and HT29) and normal human colorectal cells (HUVEC) were obtained from the Cell Bank of Chinese Academy of Science (Shanghai, China). The cell lines were cultured in DMEM (Gibco, USA) containing 10% fetal bovine serum and incubated at 37°C in a 5% CO 2 atmosphere.
Plasmid construction and cell transfection
The pcDNA3.1 vector was purchased from Invitrogen (USA) and small interfering RNA (siRNA) was obtained from Thermo Fisher Scientific (USA). pcDNA3.1-CPS1-IT1, a plasmid containing lncRNA CPS1-IT1, was constructed by Invitrogen (USA). The siRNA specifically targeting CPS1-IT1 (siRNA-CPS1-IT1) and the negative control siRNA were designed and synthesized by Thermo Fisher Scientific (USA). Colorectal cancer cell lines (LoVo and HCT116) were seeded in six-well plates at a density of 1×10 6 cells per well. Subsequently, the cells were transfected with pcDNA3.1-CPS1-IT1 or pcDNA3.1 (vector1) and CPS1-IT1-specific siRNAs or the negative control siRNA (vector2) by using Lipofectamine™ 2000 (Invitrogen, USA) according to the manufacturer's instructions. After transfection, cells were incubated for 24 h and then used for further assays.
Quantitative real-time PCR (qRT-PCR) assay
The expression of CPS1-IT1 was detected by qRT-PCR assay according to the methods described previously [51] . Total RNA was extracted from tissues and cultured cells with TRIzol reagent (Thermo Fisher Scientific, USA). The RNA samples were subjected to reverse transcription by the GoScript Reverse Transcription System (Qiagen GmbH, Germany). The sequences of the PCR primers used were as follows: CPS1-IT1, forward 5'-CAC AGA TGA TCC ACG GCG TT-3' and reverse 5'-GCG TGC ATC AAT GAC ACT TCA-3';  and GAPDH, forward 5'-CGG AGT CAA CGG ATT TGG TCG TAT TGG-3' and reverse 5'-GCT CCT GGA AGA TGG  TGA TGG GAT TTC C-3' [52] . RT-PCR analysis was performed with the ABI 7900 Detection System (Applied Biosystems, USA). The relative expression of RNA was calculated by the 2 -ΔΔCt method. GAPDH was used as an internal reference.
Colony formation assay
Twenty-four hours after transfection, both LoVo and HCT116 cells were trypsinized, counted and seeded into 12-well plates at 100 cells per well in triplicate. The medium was replaced every 3 days during the colony growth. After incubation in DMEM for 12 days, the colonies were fixed with methanol and stained with crystal violet (Sigma, USA). The colonies were considered as survivors and counted only when they contained more than 50 cells. Colony formation rate was calculated with the following formula: colony formation rate = (number of colonies/number of seeded cells) ×100%.
Cell cycle assay
For the cell cycle analysis, the cells were trypsinized with 0.25% trypsin, washed twice with PBS, and then fixed in 70% ethanol at 4°C overnight. Subsequently, the cells were stained with 10 µl of propidium iodide (PI, Sigma, USA) that contained 10 µg RNase A (Sigma, USA) for 30 min at 4°C in the dark. Samples were analyzed using a FACScan flow cytometer (Becton-Dickinson, USA).
Annexin-V FITC/PI double staining assay
Annexin-V FITC/PI analysis was performed to determine the apoptosis of cells. The LoVo and HCT116 cells were collected by low speed centrifugation (centrifuged at 2000 r/min for 3 min) and washed twice with ice-cold PBS. Then, 300 μl binding buffer was added to the cells. Afterward, the cells were incubated with 5 μl PI and 5 μl annexin V-FITC at 4°C for 5-15 min in the dark. Finally, cell apoptosis was detected within 60 min by flow cytometry (Cytomics TM FC 500, USA).
Wound-healing assay
Cell migration activity was analyzed using a wound-healing assay. Treated LoVo and HCT116 cells were plated onto 6-well plates at a density of 5×10 5 cells per well and cultured to 100% confluence. Afterward, cells were scraped with a pipette tip (tips range in volume from 1 to 200 μl) in a cross pattern in the center of each well, washed with PBS, and immediately given fresh low-serum medium. Forty-eight hours after 
Transwell assay
Cell invasion was determined by Transwell assays. The membrane of the chamber was coated with 30 mg/cm 2 Matrigel (BD Biosciences, USA) for 1 h at 37°C to form a matrix barrier. The lower chambers were filled with 600 μl of medium (DMEM supplemented with 10% FBS). The cells were suspended in DMEM to a concentration of 1×10 5 cells per well and were loaded into each upper well in a 200 µl total volume. After the chambers cultured in 5% CO 2 at 37°C for 24 hours, cells were fixed with methanol for 10 min and stained with crystal violet for 10 min. Subsequently, cells were washed with PBS. Counts were obtained from five random fields at 200× magnification.
Western blotting assay
The expression of E-cadherin, ZO-1, N-cadherin and vimentin was detected by Western blot analysis. The transfected cells or murine tumor tissues were lysed in 200 μl RIPA lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% SDS, 1% sodium deoxycholate, 1 mM EDTA, 1% Triton X-100 and protease inhibitors. Then, the proteins were separated with 10% SDS-PAGE prior to being transferred onto nitrocellulose (NC) membranes (Amersham Bioscience, U.K.). Following blocking with skim milk, the membranes were incubated with primary antibodies against E-cadherin, ZO-1, N-cadherin, vimentin and β-actin overnight. All these antibodies were purchased from Sigma (USA). Chemiluminescent signals were visualized using ECL detection reagents (Amersham Biosciences, Sweden). β-actin was used as a control. Each protein sample was examined in triplicate.
Lentiviral infection and in vivo metastasis assays
For the CPS1-IT1 shRNAs, self-complementary oligonucleotides carrying siRNAs against human CPS1-IT1 were designed (Sunbio, China). This product was cloned into the pMagic 4.1 lentiviral vector (pMagic-CPS1-IT1-shRNA) (Clontech, USA) at AgeI and EcoRI sites, and the pMagic 4.1 vector was used as the negative control (Lenti-vector2). For generation of recombinant CPS1-IT1 for overexpression, the human CPS1-IT1 sequence was amplified by PCR from a cDNA template. This product was cloned into the pLVX-EGFP-3FLAG lentiviral vector (Clontech, USA) at EcoRI sites. Thus, the pLVX-CPS1-IT1 vector was created and the pLVX-EGFP-3FLAG vector (Lenti-vector1) was used as the negative control. Subsequently, LoVo cells were infected with the viral suspensions. LoVo cell lines ( 1×10 6 ) stably expressing CPS1-IT1 or CPS1-IT1 shRNAs were injected into the tail veins of nude mice. Tumor volume was measured every three days using digital calipers and recorded. For the in vivo metastasis assays, mice were sacrificed at 45 days. The tumor weight was measured. Lung and liver metastases were examined using H&E staining with a microscope.
Statistical analysis
All data were analyzed with SPSS 17.0 (SPSS Inc, USA) and expressed as the mean ± S.D. Student's t-test was used to analyze differences between two groups. One-way ANOVA was used to perform the multisample analysis. Survival analysis was estimated by Kaplan-Meier method. All statistical tests were twosided, and a P value less than 0.05 was considered significant.
Results

CPS1-IT1 expression is decreased in CRC
To interpret the biological functionality of lncRNA CPS1-IT1 in colorectal carcinoma, we first detected CPS1-IT1 expression in 24 paired colorectal cancer tissues and adjacent noncancerous normal tissues using qRT-PCR. The results revealed that the relative expression of CPS1-IT1 was notably decreased in colorectal tumor tissues compared to their adjacent non-cancerous counterparts (p < 0.001), indicating a potential role of CPS1-IT1 as a tumor suppressor (Fig. 1A) . 
Decreased CPS1-IT1 expression is associated with poor prognosis of colorectal cancer
To assess the clinical significance of CPS1-IT1, we further studied the relationship between the expression of CPS1-IT1 and survival outcome in 24 colorectal cancer patients. The patients were subclassified into high CPS1-IT1 expression (≥ median value of expression) and low CPS1-IT1 expression (< median value of expression) groups. The acquired data were subsequently subjected to Kaplan-Meier survival analysis. The results demonstrated that among the colorectal cancer cohort, lower CPS1-IT1 expression was associated with poor overall survival (Fig. 1B) .
CPS1-IT1 expression in colorectal carcinoma cell lines
To determine the influence of CPS1-IT1 in colorectal carcinoma, we detected the expression of CPS1-IT1 in different colorectal carcinoma cell lines with varying metastatic potentials. As shown in Fig. 1C , all six colorectal carcinoma cell lines exhibited considerably lower expression of CPS1-IT1 when compared with HUVECs, and the relative expression levels of CPS1-IT1 were the lowest in the highly metastatic LoVo cell line and the highest in the weakly metastatic HCT116 cell line. Therefore, these two cell lines were chosen for use in the subsequent assays. These data show that lncRNA CPS1-IT1 was down-regulated in human colorectal carcinoma in vitro.
The influence of CPS1-IT1 on cell proliferation, apoptosis and cell cycle in human CRC
To further investigate the role of lncRNA CPS1-IT1 in colorectal carcinoma, a CPS1-IT1 expression plasmid was constructed and transfected into LoVo and HCT116 cells. In addition, CPS1-IT1-specific siRNAs were synthesized and transfected into LoVo and HCT116 cells. The results showed that the expression of CPS1-IT1 in the CPS1-IT1 expression plasmidtransfected group was significantly increased compared with the vector1 group in both cell lines (p < 0.01) and the relative transcript levels of CPS1-IT1 were reduced in the CPS1-IT1-specific siRNA group compared with the negative control siRNA group (vector2) (p < 0.01) ( Fig. 2A, 2B) . The results mentioned above indicated that the CPS1-IT1 expression plasmid and the CPS1-IT1 siRNA were successful in modulating CPSI-IT1 expression. Subsequently, a colony formation assay was conducted using LoVo and HCT116 cells. It was shown that the colony number in LoVo and HCT116 cells was decreased upon transfection with the CPS1-IT1 expression plasmid, while the colony number in LoVo and HCT116 cells was enlarged when cells were transfected with CPS1-IT1-specific siRNA (Fig. 2C, 2D) . Afterward, we investigated the potential role of CPS1-IT1 in cell apoptosis. The results showed that the apoptotic rates Kaplan-Meier analysis of overall survival according to CPS1-IT1 expression levels was performed. High CPS1-IT1 expression (≥ median value of expression) and low CPS1-IT1 expression (< median value of expression) were used to define groups. C. LoVo and SW620 were highly metastatic cell lines, SW480 and LS174T were moderately metastatic cell lines, and HCT116 and HT29 were weakly metastatic cell lines. HUVEC were used as a control.
*** p<0.001. were increased upon treatment with the CPS1-IT1 expression plasmid, while the apoptotic rates were decreased when transfected with CPS1-IT1 siRNA (Fig. 3A, 3B ). In addition, flow cytometric analysis was carried out to explore the effect of lncRNA CPS1-IT1 on cell cycle progression. The results revealed that overexpression of CPS1-IT1 in LoVo and HCT116 cells increased the fraction of cells at G0/G1 phase and reduced the fraction of cells at S and G2/M phases (Fig. 3C, 3D ), while the results showed an opposite trend in LoVo and HCT116 cells with CPS1-IT1 suppression.
The effect of CPS1-IT1 on cell migration and invasion
Moreover, we determined cell migration and invasion capacity using wound-healing assays and transwell assays. The migration capacity of CPS1-IT1 overexpressing cells was decreased in comparison with the vector1 group, whereas suppression of CPS1-IT1 enhanced the cell migration capacity (Fig. 4A, 4B ). The cell invasion assays presented similar results, showing that the invasion capacity of both CPS1-IT1-overexpressing LoVo and HCT116 cell lines reduced by approximately 44% and 69%, respectively, compared with the vector1 group (Fig. 4C, 4D ). Taken together, these results showed that CPS1-IT1 inhibited cancer cell migration and invasion capacities. 
CPS1-IT1 inhibits epithelial-mesenchymal transition
Occurrence of epithelial-mesenchymal transition (EMT) during tumorigenesis may increase the invasiveness and motility of cancer cells, and malignant transformation may be related to signaling pathways that promote EMT [26] . To further assessed associations between EMT and CPS1-IT1 in colorectal cancer, we analyzed the expression of EMTassociated proteins, including E-cadherin, ZO-1, N-cadherin and vimentin in LoVo and HCT116 cell lines. Expression of vimentin and N-cadherin were decreased in CPS1-IT1-overexpressing cells, while the levels of E-cadherin and ZO-1 were increased (Fig. 5A, 5B) . 
However, the EMT-related proteins showed a reverse trend in CPS1-IT1-suppressed cells. These results demonstrated that CPS1-IT1 plays a tumor suppressive role by preventing EMT.
CPS1-IT1 suppresses tumor growth and metastasis in vivo
To further confirm the tumor suppressor role of CPS1-IT1 in colorectal cancer, in vivo xenografts were generated via tail vein injection. In accordance with previous results, the size and weight of tumors from CPS1-IT1-overexpressing xenografts was remarkably reduced compared with the lenti-vector1 group at 41 days after injection, whereas the growth of Cellular Physiology and Biochemistry
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tumors from CPS1-IT1-siRNA xenografts was increased ( Fig. 6A-6C ). Western blots were performed to demonstrate the regulation of EMT by CPS1-IT1. Like the results of the in vitro cell assay, expression of EMT-promoting proteins, such as N-cadherin and vimentin, was decreased in CPS1-IT1-overexpressing tumors, while expression of E-cadherin was increased. However, the expression of EMT-related proteins showed a reverse trend in CPS1-IT1-suppressed cells. An inhibitory effect of CPS1-IT1 on the lung and liver metastasis of colorectal carcinoma was also observed in both LoVo and HCT116 cells (Fig. 7A, 7B ).
Discussion
CRC is one of the most common malignancies worldwide and is the fourth leading cause of cancer-related death [2] . Under most circumstances, symptoms of cancer are detected at an advanced stage, leading to poor prognosis. Consequently, the exploration of new diagnostic and therapeutic biological targets for CRC is especially important. In addition to microRNAs, emerging discoveries suggest that lncRNAs are also important factors in cell biology. It has been suggested that lncRNA dysregulation is associated with a variety of human diseases, including cancer [53] [54] [55] . However, the function of lncRNAs in CRC remains unknown. In the present study, we analyzed CPS1-IT1, a novel lncRNA, and confirmed its tumor-suppressive effect in human CRC cells.
We found that the expression of CPS1-IT1 was remarkably reduced in human CRC specimens, and low CPS1-IT1 expression in human CRC was related to poor prognostic outcome. This finding was in accordance with the previous study which recognized CPS1-IT1 as a tumor suppressor in hepatocellular carcinoma [49] and lung cancer [50] . Moreover, both in vitro assays and an in vivo animal models verified that CPS1-IT1 suppresses tumor growth by reducing CRC cell proliferation, migration and invasion capacities as well as by promoting cell apoptosis, thereby suppressing EMT. Hence, these findings suggest that CPS1-IT1 might be a tumor suppressor in human CRC that could serve as a prognostic biomarker for the disease.
Tumor metastases are the primary causes of cancer-related death, and EMT is recognized to increase the motility and invasiveness of cancer cells [56, 57] . EMT is a process whereby differentiated epithelial cells undergo a transition to a mesenchymal phenotype and become motile and invasive, properties that are closely associated with metastasis [58] . In our study, we found that overexpression of CPS1-IT1 remarkably reduced cell migration and invasion capacities. In addition, expression of EMT-associated proteins, including E-cadherin, ZO-1, N-cadherin and vimentin, was reduced in CPS1-IT1-overexpressing cells. These findings suggested that CPS1-IT1 might reduce human CRC metastasis by suppressing EMT. This The Role of Lncrna CPS1-IT1 in CRC discovery was supported by prognostic analysis. Poorer overall survival was related to the decrease of CPS1-IT1 expression in CRC patients. Furthermore, the level of apoptosis increased with overexpression of CPS1-IT1, and it could be concluded that lncRNA CPS1-IT1 induced cell apoptosis. In addition, the induction of apoptotic activity is a good way to inhibit the proliferation of cancer cells [59] . All these data demonstrate that lncRNA CPS1-IT1 might be a tumor suppressor in CRC and could serve as a molecular biomarker for the diagnosis of CRC. lncRNA dysregulation causes a range of biological dysfunction and provides a cellular growth advantage, leading to progressive and uncontrolled tumor growth [60] . However, the molecular mechanisms by which lncRNAs regulate cancer cells are diverse.
lncRNAs can serve as guides for proteins to reach their targets, as regulatory signals for transcription, as hubs to localize transcription factors, as a framework to bridge different proteins, as 'sponges' to sequester microRNAs, and as molecules that can allosterically alter the functions of proteins [61, 62] . For instance, CPS1-IT1 was found to interact with HSP90 in human hepatocellular carcinoma. CPS1-IT1 is required to activate and stabilize numerous proteins involved in essential cellular processes [63] . In addition, CPS1-IT1 was also found to suppress the growth of hepatocellular carcinoma by inhibiting epithelial-mesenchymal transition and regulating HIF-1α activity [49] . The mechanism of the inhibitory effect of lncRNA CPS1-IT1 on CRC growth needs to be further studied.
Conclusion
Our data show that lncRNA CPS1-IT1 exerts a tumor-suppressive effect on human CRC cells. Specifically, CPS1-IT1 suppresses tumor growth by reducing cell proliferation, migration and invasion capacities as well as by promoting cell apoptosis, thereby suppressing EMT. Our study provides new insights into the function of lncRNAs in the development of human CRC and demonstrates that CPS1-IT1 represents a potential prognostic biomarker and therapeutic target for human CRC.
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